Michael Rosenblatt, MD

Chief Medical Officer Flagship Ventures


Dr. Rosenblatt’s career has been in academia, the pharmaceutical industry and biotech/venture. He is a physician, scientist, educator and leader in healthcare. He currently serves as an advisor to the biopharmaceutical industry and academia. Most recently, he was the Chief Medical Officer of Flagship Pioneering in Cambridge, MA, the venture firm that created Moderna, and he was part of Moderna’s vaccine team. Previously he was Chief Medical Officer for Merck and prior to that, Dean of Tufts University School of Medicine. At Harvard Medical School he was Robert Ebert Professor of Molecular Medicine and then George R. Minot Professor of Medicine. He served as President of Beth Israel Deaconess Medical Center (BIDMC) and earlier as Director of the Harvard-MIT Division of Health Sciences and Technology. While at Merck the first time, he was Senior VP for Research where he co-led worldwide development of alendronate (FOSAMAX), the leading medicine for osteoporosis. Before joining Merck, he was Chief of the Endocrine Unit at the Massachusetts General Hospital.

Dr. Rosenblatt has been active in the biotechnology industry, serving on the board of directors and scientific advisory boards of several biotech companies. He was a scientific founder of ProScript, which discovered bortezomib (Velcade) for multiple myeloma, and Radius Pharmaceuticals, a company that has developed abaloparatide (TYMLOS) for osteoporosis. He is also currently on the Harvard Medical School Board of Fellows, and research advisory committees of the Massachusetts General Hospital, and Children’s Hospital (Boston).

Dr. Rosenblatt received his undergraduate degree summa cum laude from Columbia and his MD magna cum laude from Harvard. His internship, residency, and endocrinology training were all at the Massachusetts General Hospital.